Equities

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)7.20
  • Today's Change0.12 / 1.69%
  • Shares traded740.49k
  • 1 Year change-15.89%
  • Beta1.4435
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments350389466
Total Receivables, Net241315
Total Inventory402519
Prepaid expenses9.491412
Other current assets, total1.151.420.80
Total current assets425443513
Property, plant & equipment, net1178.569.80
Goodwill, net------
Intangibles, net4.986.438.40
Long term investments0.20--0
Note receivable - long term------
Other long term assets1.521312
Total assets548471543
LIABILITIES
Accounts payable4.333.093.88
Accrued expenses502932
Notes payable/short-term debt000
Current portion long-term debt/capital leases15----
Other current liabilities, total7.875.814.64
Total current liabilities774641
Total long term debt7500
Total debt9000
Deferred income tax------
Minority interest------
Other liabilities, total171924
Total liabilities1706564
SHAREHOLDERS EQUITY
Common stock1,2001,1851,177
Additional paid-in capital1218559
Retained earnings (accumulated deficit)(942)(864)(756)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.73)(1.06)(0.85)
Total equity378405479
Total liabilities & shareholders' equity548471543
Total common shares outstanding144142142
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.